The days of siloed approaches to chronic conditions such as HIV are over
In Conversation
We now have the scientific tools to end the HIV epidemic; the challenge lies in delivery
ISPOR sits at the nexus of science and policy, and we advocate that the best policies always rest on a foundation of good science
Astellas has steadily developed its immuno-oncology (IO) pipeline via both organic and inorganic means in recent years, with its early-phase IO projects now overseen by industry…
In 2023, we face a new digital relations landscape where a customer and a brand more and more rely on personal data exchange and unique communication…
DIA today is a vastly different organization than it was. Our emphasis on catalyzing thought leadership and applying our global platform and channels to convene, conduct…
... if high drug prices are the problem – and this administration says that a lot – then generics and biosimilars are the solution. I think…
... the Ichnos team has further accelerated our clinical stage pipeline in haematological malignancies to better position the firm and prepare it to host new investors…
I am a great believer in the US system and feel that there is a lot of misinformation about it.
The patient is ultimately the reason why we work in this industry, but historically the patient experience has tended to be sidelined
A lot of work is going on to increase funding for paediatric cancer and many centres – mine included – are not necessarily waiting around for…
If companies bring in the patient perspective from the beginning, the insights they gain could make their clinical trial process go quicker and create a better…
